Infinity Pharmaceuticals, Inc. and MedImmune, Inc. (MEDI) Present Updated Phase I Results of IPI-504 in GIST at American Society of Clinical Oncology Annual Meeting  
6/5/2007 1:31:09 PM

CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced updated interim results from a Phase I clinical trial of the companies' heat shock protein 90 (Hsp90) inhibitor, IPI-504, in patients with relapsed, refractory gastrointestinal stromal tumors (GIST) and other advanced soft tissue sarcomas. The data, presented at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), indicate that IPI-504 continues to be well tolerated and to show evidence of biological activity.